
Weekly Enforcement Update: Inflated Claims Are a Key Theme
Though last week’s cases didn’t involve labs or lab testing, most were FCA-related issues including inflated claims.
Though last week’s cases didn’t involve labs or lab testing, most were FCA-related issues including inflated claims.
Last week saw the usual False Claims Act and kickback-related charges, with the biggest action involving urine drug testing.
Most of last week’s healthcare-related actions involved telemedicine in some way, with the lone lab-related case centering on genetic testing.
While labs were absent from recent enforcement actions, last week saw kickback schemes involving DME companies and a medical device company.
Case is a recent example of the trend toward Medicare schemes involving telehealth, cancer genetic testing, and kickbacks.